Why the study?
Does the METS-VF score predict the future onset of diabetes better than other adiposity indicators in the NAGALA cohort?
Does the METS-VF score predict the future onset of diabetes better than other adiposity indicators in the NAGALA cohort?
The novel METS-VF score may serve as a superior clinical tool for predicting medium- and long-term diabetes risk compared to traditional adiposity indicators.
May aid diabetes risk stratification in cohorts; leaves open prospective validation before practice change.
METS-VF, a novel indicator for assessing visceral adiposity, showed a significantly positive correlation with diabetes risk. It proved to be a superior risk marker in predicting the future onset of diabetes compared to other general/visceral adiposity indicators, particularly in forecasting medium- and long-term diabetes risk.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: